LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Chiusa

SettoreSettore sanitario

16.65 2.59

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.14

Massimo

16.88

Metriche Chiave
By Trading Economics
Entrata	614M 331M
Vendite	288M 731M
P/E Media del settore	48.586 49.888
EPS	3.16
Margine di Profitto	45.287
Dipendenti	835
EBITDA	628M 375M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+36.45% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-531M 1.8B
Apertura precedente	14.06
Chiusura precedente	16.65

Notizie sul Sentiment di mercato

By Acuity

50%

155 / 344 Classifica in Healthcare

Sarepta Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 lug 2025, 15:04 UTC

I principali Market Mover

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21 lug 2025, 11:31 UTC

I principali Market Mover

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26 gen 2026, 09:55 UTC

Azioni calde

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4 nov 2025, 14:39 UTC

Utili

Azioni calde

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4 nov 2025, 12:45 UTC

Utili

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11 ago 2025, 11:48 UTC

Utili

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11 ago 2025, 11:11 UTC

Utili

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29 lug 2025, 21:11 UTC

Utili

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29 lug 2025, 12:14 UTC

Utili

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29 lug 2025, 11:46 UTC

Utili

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21 lug 2025, 12:53 UTC

Utili

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 lug 2025, 11:17 UTC

Utili

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 lug 2025, 10:25 UTC

Utili

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 lug 2025, 09:50 UTC

Utili

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 lug 2025, 09:12 UTC

Utili

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 lug 2025, 16:44 UTC

Utili

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 lug 2025, 13:48 UTC

Utili

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 lug 2025, 10:57 UTC

Utili

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 lug 2025, 09:08 UTC

Azioni calde

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 giu 2025, 09:10 UTC

Azioni calde

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 giu 2025, 08:59 UTC

Azioni calde

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 giu 2025, 08:55 UTC

Azioni calde

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Confronto tra pari

Modifica del prezzo

Sarepta Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

36.45% in crescita

Previsioni per 12 mesi

Media 22.16 USD 36.45%

Alto 38 USD

Basso 5 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sarepta Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Sarepta Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

155 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.